MedTrace Logo

Low Dose IL-2 for Ulcerative Colitis

NCT02200445 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-06-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe ulcerative colitis.

Conditions

Interventions

DRUG

Interleukin-2 (aldesleukin).

Description of intervention is covered in "Arm", above.

Sponsors & Collaborators

  • Scott B. Snapper, MD PHD

    lead OTHER

Principal Investigators

  • Scott B Snapper, MD PhD · Boston Children's Hospital

  • Jessica R Allegretti, MD, MPH · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2020-10-01
Completion
2021-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02200445 on ClinicalTrials.gov